Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of ...

Shares of Viatris Inc. VTRS slipped 1.03% to $10.62 Monday, on what proved to be an all-around positive trading session for ...

Shares of Viatris Inc. VTRS rose 1.89% to $10.80 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.04% to 6,115.07 and the ...

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other high-yield dividend stocks. Dividend stocks have been investors’ favorites for a long ...

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

Novartis and Viatris have become the latest pharma companies to be named in lawsuits claiming that they profited from the unlawful use of HeLa cells derived from cells taken from a cancer patient ...

Viatris' earnings beat was driven by effective cost management. For fiscal 2024, analysts anticipate Viatris to report an EPS of $2.68, down 8.5% from $2.93 in fiscal 2023 .

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...